Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b

Journal of Clinical Virology

Volumn 55, Issue 1, 2012, Pages 58-61

  Vispo, Eugenia ^a   Rallon, Norma I ^a   Labarga, Pablo ^a   Barreiro, Pablo ^a   Benito, Jose Miguel ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Coinfection; HCV 1 subtypes; Hepatitis C; IL28B

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALLELE; ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IL 28B GENE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84865195864     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.05.012     Document Type: Article

References (32)

1. EASL EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264.
2. Manns M., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55:1350-1359.
3. Ge D., Fellay J., Thompson A., Simon J., Shianna K., Urban T., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
4. Medrano J., Neukam K., Rallon N., Rivero A., Resino S., Naggie S., et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV. Clin Infect Dis 2010, 51:1209-1216.
5. Poordard F., McCone J., Bacon B., Bruno S., Manns M., Sulkowski M., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
6. Poordard F, Bronowicki JP, Gordon S, Zeuzem S, Jacobson I, Sulkowski M, et al. Factors that predict response of patients with HCV infection to boceprevir. Gastroenterology, in press.
7. Jacobson I., McHutchison J., Dusheiko G., Di Bisceglie A., Reddy K., Bzowej N., et al. Telaprevir combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 ADVANCE study. 61st American Association for the Study of Liver Diseases (AASLD) 2010, [Abstract 211].
8. Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz E, Horban A, et al. Similar SVR rates in IL28B CC, CT or TT prior relapsers, partial or null responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. In: Abstracts of the 46th EASL annual meeting. Berlin, Germany; 2011 [Abstract 13]. J Hepatol 2011;54(Suppl. 1):6-7.
9. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2009, 138:447-462.
10. Halfon P., Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011, 55:192-206.
11. Zeuzem S., Buggisch P., Agarwal K., Marcellin P., Sereni D., Klinker H., et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012, 55:749-758.
12. Brainard M., Anderson M., Petry A., Narjes F., Crescenzi B., Ferrara M., et al. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281 in treatment-naïve genotype 1A, 1B and 3 HCV-infected patients. Hepatology 2009, 50(Suppl.):1026-1027.
13. McPhee F, Hernandez D, Yu F, Friborg J, Levine S, Chen C, et al. Characterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052. In: Abstracts of the 46th EASL annual meeting. Berlin, Germany; 2011 [Abstract 63]. J Hepatol 2011;54(Suppl. 1):28-9.
14. Lenz O, Fevery B, Vijgen L, Berg T, Tanwandee T, Thongsawat S, et al. TMC-435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virological analyses of the ASPIRE trial. In: 47th EASL. Barcelona, April 18-22; 2012 [Abstract 9]. J Hepatol 2012;56(Suppl. 1):5.
15. Soriano V., Puoti M., Sulkowski M., Cargnel A., Benhamou Y., Peters M., et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panel. AIDS 2007, 21:1073-1089.
16. Chevaliez S., Bouvier-Alias M., Brillet R., Pawlotsky J.M. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009, 4:e8209.
17. Ziol M., Handra-Luca A., Kettaneh A., Christidis C., Mal F., Kazemi F., et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54.
18. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Hasser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
19. de Ledinghen V., Douvin C., Kettaneh A., Ziol M., Roulot D., Marcellin P., et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006, 41:175-179.
20. Kirk G., Astemborski J., Mehta S., Spoler C., Fisher C., Allen D., et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009, 48:963-972.
21. Livak K. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999, 14:143-149.
22. Medrano J., Resino S., Vispo E., Madejón A., Labarga P., Tuma P., et al. Hepatitis C virus uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat 2011, 18:325-330.
23. Alestig E., Arnholm B., Eilard A., Legging M., Nilsson S., Norkrans G., et al. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2011, 11:124.
24. Hayashi K., Katano Y., Kuzuya T., Tachi Y., Honda T., Ishigami M., et al. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated interferon-alpha 2b and ribavirin. J Med Virol 2012, 84:438-444.
25. Manns M., McHutchison J., Gordon S., Rustgi V., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
26. Fried M., Shiffman M., Reddy K., Smith C., Marinos G., Gonçales F., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
27. Hadziyannis S., Sette H., Morgan T., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
28. McCown M., Rajyaguru S., Kular S., Cammack N., Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009, 53:2129-2132.
29. Kieffer T., Kwong A., Picchio G. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010, 65:202-212.
30. Soriano V., Peters M., Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis 2009, 48:313-320.
31. Jensen D. A new era of hepatitis C therapy begins. N Engl J Med 2011, 364:1272-1274.
32. Soriano C. A new era for hepatitis C - diagnostic tools and new weapons. ACS Chem Biochem; in press.